Item 7.01 Regulation FD Disclosure.
Over the last week, BioMarin Pharmaceutical Inc. (the “Company” or “BioMarin”) has received numerous inquiries regarding elements of its long-term financial guidance and outlook that the Company communicated on September 4, 2024 during its webcast Investor Day. To facilitate future conversations in compliance with Regulation FD, today the Company is reaffirming its long-term financial guidance and outlook that it presented during Investor Day, including, without limitation, that the Company anticipates the following:
| |
• |
|
approximately $4 billion in total revenues in 2027; |
| |
• |
|
40% Non-GAAP Operating Margin starting in 2026 and growing to the low- to mid-40% range over time; |
| |
• |
|
more than $1.25 billion operating cash flow per year starting in 2027; |
| |
• |
|
mid-teen compound annual growth rate (CAGR) for total revenues through 2034; and |
| |
• |
|
potential treatments for skeletal conditions to represent a greater than $5 billion revenue opportunity over time. |
Forward-Looking Statements
This current report on Form 8-K contains forward-looking statements about the business prospects of the Company, including, without limitation, statements regarding the Company’s future financial performance, including the expectations of Total Revenues, Non-GAAP Operating Margin percentage, Operating Cash Flow and Revenue Compound Annual Growth Rate (CAGR); and the size of the revenue opportunity for potential treatments for skeletal conditions.
These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others, those factors detailed in BioMarin’s Investor Day presentation and press release issued September 4, 2024 and BioMarin’s filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as such factors may be updated by any subsequent reports. You should carefully consider that information before you make an investment decision. You should not place undue reliance on forward-looking statements, which speak only as of the date hereof. These forward-looking statements are based on the beliefs and assumptions of the Company’s management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that the Company may issue in the future as well as other cautionary statements the Company has made and may make. Except as required by law, BioMarin does not undertake any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
Non-GAAP Information
The guidance included in this Form 8-K includes both GAAP information and Non-GAAP information. Non-GAAP Operating Margin percentage is defined by the Company as GAAP Income from Operations, excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, divided by GAAP Total Revenues.
BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. Because Non-GAAP Operating Margin percentage is an important internal measurement for BioMarin, the Company believes that providing this information in conjunction with BioMarin’s GAAP information enhances investors’ and analysts’ ability to meaningfully compare the Company’s results from period to period and to its forward-looking guidance, and to identify operating trends in the Company’s principal business.
Non-GAAP information and its components are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its Non-GAAP financial measures; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this Form 8-K may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
